Nuclease resistant chimeric oligonucleotides
AssigneeIsis Pharmaceuticals, Inc.
InventorsMuthiah Manoharan, Martin A. Maier, Thazha P. Prakash, Kallanthottathil G. Rajeev
Life of this patent
Estimating the term…
Loading patent…
AssigneeIsis Pharmaceuticals, Inc.
InventorsMuthiah Manoharan, Martin A. Maier, Thazha P. Prakash, Kallanthottathil G. Rajeev
Estimating the term…
The present invention relates to novel nuclease-resistant oligomeric compounds and to novel methods for increasing the nuclease resistance of oligomeric compounds. In preferred embodiments of the invention, the oligomeric compounds comprise at least one modified nucleoside containing a modified sugar moiety at either the 3′ or 5′ terminus of the oligomeric compound, and further comprise at least one internucleoside linking group that is other than phosphodiester. Other preferred embodiments of the invention include methods of enhancing the nuclease resistance of oligomeric compounds comprising incorporating at least one modified nucleoside containing a modified sugar moiety at either the 3′ or 5′ terminus of an oligomeric compound.
An oligomeric compound of formula V:
A method of enhancing the nuclease resistance of an oligomeric compound comprising providing at least one modified nucleoside at either the 3′ or 5′ terminus of said oligomeric compound to give a modified oligomeric compound of formula V:
Dependencies are inferred from the claim text.